In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting with Cetuximab/Trastuzumab Is More Effective than Treatment with Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptors' Down-regulation and Dimers' Disruption.

Christel Larbouret 1 Nadège Gaborit 1 Thierry Chardès 1 Mickaël Coelho 1 Emmanuelle Campigna 1 Caroline Bascoul-Mollevi 2 Jean-Pierre Mach 3 David Azria 1, 2 Bruno Robert 1 André Pèlegrin 1, *
* Auteur correspondant
1 IRCM - U896 Inserm - UM1 - Institut de recherche en cancérologie de Montpellier
2 CRLC Val d'Aurelle-Paul Lamarque
3 Institut de Biochimie
Abstract : We previously demonstrated the synergistic therapeutic effect of the cetuximab (anti-epidermal growth factor receptor [EGFR] monoclonal antibody, mAb)-trastuzumab (anti-HER2 mAb) combination (2mAbs therapy) in HER2(low) human pancreatic carcinoma xenografts. Here, we compared the 2mAbs therapy, the erlotinib (EGFR tyrosine kinase inhibitor [TKI])-trastuzumab combination and lapatinib alone (dual HER2/EGFR TKI) and explored their possible mechanisms of action. The effects on tumor growth and animal survival of the three therapies were assessed in nude mice xenografted with the human pancreatic carcinoma cell lines Capan-1 and BxPC-3. After therapy, EGFR and HER2 expression and AKT phosphorylation in tumor cells were analyzed by Western blot analysis. EGFR/HER2 heterodimerization was quantified in BxPC-3 cells by time-resolved FRET. In K-ras-mutated Capan-1 xenografts, the 2mAbs therapy gave significantly higher inhibition of tumor growth than the erlotinib/trastuzumab combination, whereas in BxPC-3 (wild-type K-ras) xenografts, the erlotinib/trastuzumab combination showed similar growth inhibition but fewer tumor-free mice. Lapatinib showed no antitumor effect in both types of xenografts. The efficacy of the 2mAbs therapy was partly Fc-independent because F(ab')(2) fragments of the two mAbs significantly inhibited BxPC-3 growth, although with a time-limited therapeutic effect. The 2mAbs therapy was associated with a reduction of EGFR and HER2 expression and AKT phosphorylation. BxPC-3 cells preincubated with the two mAbs showed 50% less EGFR/HER2 heterodimers than controls. In pancreatic carcinoma xenografts, the 2mAbs therapy is more effective than treatments involving dual EGFR/HER2 TKIs. The mechanism of action may involve decreased AKT phosphorylation and/or disruption of EGFR/HER2 heterodimerization.
Keywords : EGFR HER2 monoclonal antibodies tyrosine kinase inhibitor pancreatic cancer HERdimerization
Type de document :
Article dans une revue
Neoplasia : An International Journal for Oncology Research, Elsevier, 2012, 14 (2), pp.121-30
Liste complète des métadonnées

Littérature citée [38 références]  Voir  Masquer  Télécharger
http://www.hal.inserm.fr/inserm-00682017
Contributeur : Yves Le Ster <>
Soumis le : vendredi 6 septembre 2013 - 14:39:12
Dernière modification le : mercredi 3 octobre 2018 - 16:02:20
Document(s) archivé(s) le : vendredi 31 mars 2017 - 02:50:45

Fichier

Larbouret_Neoplasia_2012_12020...
Fichiers produits par l'(les) auteur(s)

Identifiants

  • HAL Id : inserm-00682017, version 1
  • PUBMED : 22431920

Collections

FNCLCC | VALDAURELLE | BS | UNIV-MONTPELLIER

Citation

Christel Larbouret, Nadège Gaborit, Thierry Chardès, Mickaël Coelho, Emmanuelle Campigna, et al.. In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting with Cetuximab/Trastuzumab Is More Effective than Treatment with Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptors' Down-regulation and Dimers' Disruption.. Neoplasia : An International Journal for Oncology Research, Elsevier, 2012, 14 (2), pp.121-30. 〈inserm-00682017〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

721

Téléchargements de fichiers

295

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD